UK’s NICE Seeks Feedback On Proposed Improvements To Its Processes
Proposals extend the health technology appraisal body's focus beyond final guidance to support for early development and real world performance.
You may also be interested in...
Companies selling gene therapies and other high-cost, long-term treatments may be disappointed but unsurprised to learn that NICE will not immediately introduce any change to discount rates, which are used in health technology appraisals to better understand the long-term costs and benefits.
The COVID-19 pandemic has offered lessons on how collaboration can get important treatments to patients more quickly.
NICE will develop standards for using real world data as part of a new five-year strategic plan that the UK health technology assessment body hopes will make it a leader in the use of research and data.